These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11735676)

  • 1. Cost effectiveness of treatment options in advanced breast cancer in the UK.
    Brown RE; Hutton J; Burrell A
    Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
    Launois R; Reboul-Marty J; Henry B; Bonneterre J
    Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
    Benedict A; Cameron DA; Corson H; Jones SE
    Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
    Launois RJ; Reboul-Marty JM; Bonneterre J
    Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
    Brown RE; Hutton J
    Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
    Frías C; Cortés J; Seguí MÁ; Oyagüez I; Casado MÁ
    Clin Transl Oncol; 2010 Oct; 12(10):692-700. PubMed ID: 20947484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of taxane therapy.
    Yee GC
    Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
    Dranitsaris G; Elia-Pacitti J; Cottrell W
    Pharmacoeconomics; 2004; 22(6):375-87. PubMed ID: 15099123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
    Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
    Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and docetaxel. Innovation, but at what cost?
    Lønning PE
    Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
    [No Abstract]   [Full Text] [Related]  

  • 17. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer.
    Hutton J; Brown R; Borowitz M; Abrams K; Rothman M; Shakespeare A
    Pharmacoeconomics; 1996; 9 Suppl 2():8-22. PubMed ID: 10163967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost utility in second-line metastatic breast cancer.
    Berdeaux G; Hurteloup P
    Pharmacoeconomics; 1997 May; 11(5):492-7. PubMed ID: 10168037
    [No Abstract]   [Full Text] [Related]  

  • 19. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
    Ibrahim NK; Sahin AA; Dubrow RA; Lynch PM; Boehnke-Michaud L; Valero V; Buzdar AU; Hortobagyi GN
    Lancet; 2000 Jan; 355(9200):281-3. PubMed ID: 10675076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.